DTC fair balance review, explained.

Fair balance explained: a 60-second ad, a list of risks, and how much of them a viewer can take in

One spot's road to air, from a script to a filed Form 2253

1. The brand team and agency write the scriptClaims are checked against the label on paper, along with the major statement's wording, before anything is filmed.
2. The agency shoots and edits a cutPicture, voice, on-screen text and music come together for the first time. The risks now share the screen with everything else.
3. Reviewers check the fair balance of the cutRisk against benefit, and what the picture, text, voice and music do during the major statement. This is where 8 shot changes under one risk line are caught, or aired.
4. The agency revises, and the next cut is checked againEach round spends days against a media date already paid for.
5. People sign, and the ad airs with a form filedRegulatory and legal sign. The ad goes to FDA on Form FDA 2253 when it first runs. FDA does not normally approve an ad first.2,3

Step 3 is the subject of this guide. FDA sees the ad on the form after it starts running, so the company's own review is the only check most ads get before viewers see them.

Why a shot count cannot clear an ad, and three more surprises

Major statement, super, cut and untitled letter: the four words to learn first

Twelve terms are defined in the one-page summary.

Fair balance and the major statement are two tests, and a TV drug ad has to pass both

In shortFair balance looks at the whole ad: are risk and benefit given comparable prominence and depth? The major statement standards look at one passage: can a viewer take in the risks while they are being presented? An ad can give risk plenty of seconds and still fail the second test.

The older test is in 21 CFR 202.1(e)(5)(ii), a paragraph of FDA's prescription drug advertising regulation. An ad's statement is untrue if it "fails to present a fair balance" between side effect information and effectiveness information.2

Paragraph (e)(7)(viii) adds how FDA looks at it: an ad may be misleading if it fails to present risks "with a prominence and readability reasonably comparable" to effectiveness, taking in "typography, layout, contrast, headlines, paragraphing, white space".2 Those words were written with print in mind, and FDA still uses them, on an Instagram post as recently as September 2026.9

The newer test is in (e)(1)(ii), and it covers only ads for human prescription drugs presented directly to consumers in television or radio format that name the drug and its use.2,4 Reminder ads, which name a drug and say nothing of what it treats, are exempt from the brief summary requirement, explained below, which is where the major statement sits.2 Prescription device ads sit under different provisions and are outside this rule.

Why the seconds alone settle little: three spots with the same 21 seconds

Major statement, brief summary and adequate provision: how the three fit together

A print ad carries a brief summary, a page of risk text. Broadcast cannot, so (e)(1)(i) asks a broadcast ad for two things: the major statement in the ad, and a brief summary "unless adequate provision is made for dissemination of the approved or permitted product labeling".2 In plain words, adequate provision means pointing viewers to the full labeling somewhere else. FDA's 1999 guidance gives one accepted way to do it, in four parts:10

That is why so many spots end with a phone number and "see our ad in" a magazine. Section 9 covers FDA's plan to remove this option.

The rules on drug ad risk, from a 1960s regulation to a proposal due in December 2026

In shortCongress asked for "clear, conspicuous and neutral" in 2007. FDA proposed standards in 2010 and finished them in 2023, with a compliance date of November 20, 2024. Enforcement came in September 2025. FDA's next step, removing adequate provision, is listed for a proposal in December 2026 and has not been published.

Civil money penalties for a false or misleading DTC ad exist in law: currently up to $377,701 for a first violation in three years and $755,402 for each later one.18 We read the 87 letters of 2025 and 2026 and did not see them used in those letters.1

Language, voice, text timing, legibility and interference: the five standards for a major statement

In shortA major statement is clear, conspicuous and neutral if five things hold. Two of them apply only to TV. All five are written as outcomes: readily understandable, read easily, likely to interfere. FDA says more than one combination of font, size and contrast can pass, so a reviewer has to weigh them together.

What dual modality asks that many supers miss

Dual modality means the major statement is spoken and shown as text at the same time. The rule is stricter than it first looks. Text has to carry words from the audio, verbatim, and it has to run with the audio. Two problems follow. A gap in the text while the voice goes on leaves part of the major statement in one channel.

Text that says something the voice does not is its own problem: 2025 and 2026 letters object to "information in the SUPERs that is not from the corresponding audio".5,19 A risk that appears in a super and is never spoken also fails the first requirement of the major statement, because the major statement must be in the audio.2,19

What FDA's evidence shows, one element at a time

What we found reading FDA's 87 untitled letters of 2025 and 2026

In shortFDA's list shows 63 untitled letters in 2025 against 5 in 2024, and 24 so far in 2026. We read all 87. Forty-nine are about TV ads, and 37 of those object to how the major statement was presented. Interference is the leading objection. Voice pace, which the rule covers, appears in none of them.

The words FDA used, quoted from real letters

FDA writes "frequent" and gives no count in the letters we read, so nobody outside the agency knows where frequent begins. It names what is on screen, often as a list of small actions, so a review record that describes the picture will read much like the letter would. And one company can draw several letters at once: three on different ads for one drug, all listed under September 9, 2025, with largely the same concerns.26,1

Other counts differ because they were taken on other days or cover other letters. FDA Law Blog counted 40 untitled and 35 warning letters on September 16, 2025, and ProPharma found 43 of 48 posted that week cited a consumer TV or video ad.27,28 We count only untitled letters, on the list as it stood on October 16, 2026, and we did not read warning letters for this chart.

Measuring a cut with arithmetic: shot rate, text coverage, size, contrast, reading speed and music

In shortMost of what the five standards touch can be counted from the file: shots per 10 seconds, the share of the major statement with text, text height as a share of the frame, contrast, words per second, loudness. FDA's letters already use one such formula, for reading speed. The numbers below come from the guide's fictional spot and its sample limits. No regulator has set these limits.

The sums behind six measures on one 60-second cut

Where those limits come from: the contrast figure matches WCAG 2.2's level AA line for ordinary text, a web accessibility standard.29 The others are the fictional company's judgment, each one written down so it can be defended and changed. Write down why you chose yours.

FDA's reading-speed test: words on screen, divided by seconds

This one comes from FDA. In several letters it takes a super, counts its words, divides by the seconds on screen and compares the result with a published review finding that adults read about 238 words a minute, most between 175 and 300.30,31,32,33 The three TV cases below concern supers that qualify a benefit claim. A fourth letter, on a social media reel, applies the same sum to scrolling text: 2,640 words a minute for the first five seconds, then an estimated 5,184.34

Running FDA's sum on the fictional spot

Cut 4's first risk super reads "Serious infections can occur. Tests for tuberculosis before starting." Nine words in 9 seconds is 60 words a minute, far inside the range, so reading speed is not its problem: its size and contrast are.

Now suppose the agency had answered with a full transcript in place of key terms. The voice reads 67 words in 21 seconds, so a verbatim super would run at about 191 words a minute, inside the range and near its low end, before you count what else the eye has to do. Fair warning: FDA's figure comes from people reading uninterrupted non-fiction, and a viewer of an ad is doing far more than that.

When the montage promises more than the label: quality of life, disclaimers and the overall impression

In shortA second family of objections has nothing to do with timing. FDA reads the story an ad tells. In 14 of the 49 TV ad letters it raises quality of life, emotional or social implications, often because the studies behind the drug never measured them. A "results may vary" super does not repair it.

The plaque psoriasis letter quoted above is a good example. A man reminisces alone, gets his drug, and is then shown happy at the barber and with friends. FDA notes that the trials measured itching, pain and scaling and did not measure emotional or social functioning, so the ad "misleadingly suggests" a health-related quality of life benefit that "has not been demonstrated".22

The super "Results may vary" appeared, and FDA says it "does not correct or mitigate the misleading impression".22 A law firm's reading of the early 2026 letters adds that FDA judges net impression and that visuals implying emotional relief or hope beyond the data drew objections.35

So the question for the medical reviewer has two halves. Is each spoken and written claim supported by the label? And what does the picture say that nobody says out loud?

A label that supports skin clearance at week 16 says nothing about kayaking. The way to catch this in review is to set the story beside the label's clinical section, shot by shot, and ask what endpoint would support each shot. Under 21 CFR 202.1(e)(6)(xviii), an ad that uses a picture in a misleading way counts as false, lacking in fair balance or otherwise misleading.2

Streaming cuts, creator posts and brand web pages: which rule follows the ad off television

In shortThe five standards are written for "television or radio format", and the rule's text does not use the word streaming. FDA uses the same language for a video and a TV ad of one drug. Web pages and social posts fall under the fair balance and prominence rules. A company's spokesperson counts as promotion, and a "link in bio" leaves the risks out of the post.

In April 2026, FDA wrote about a video and a TV ad for one cancer drug together: "the video and TV ad are misleading because they fail to present the major statement concurrently using both audio and text".38 A reviewer treating a streaming cut as outside the major statement standards would be taking a risk FDA's own wording does not encourage.

Online content draws letters too. Interviews with a company's spokesperson drew three letters for presenting how well the drug works and omitting all risk information.39,1 An Instagram post drew a September 2026 letter citing (e)(5) and (e)(7)(viii).9

Which rule to read first for a TV spot, a streaming cut, a web page or a post

If adequate provision goes: the December 2026 proposal, longer ads and what they do to review

In shortFDA's agenda lists a proposed rule for December 2026 that would end adequate provision. A broadcast ad would then have to carry its full brief summary. Lawyers call that a possible de facto ban and expect a fight. It is not law, and no text is published. Meanwhile ad length has risen, and the counts of TV spending since the letters point in different directions.

The Unified Agenda is the federal government's report of rules in development. The entry here is RIN 0910-AJ14, "Transparency in Direct-to-Consumer Advertising". It says the rule will revise 21 CFR 202.1 to eliminate the option and lists a notice of proposed rulemaking in December 2026, marked economically significant.12 We found no Federal Register notice on November 3, 2026, and OIRA, the White House office that reviews significant rules before they publish, did not list it among the rules under review that day.40

Some headlines say "FDA proposes"; they describe this listing.41 FDA Law Blog argues the change could effectively ban broadcast ads by making them too long and costly, and expects litigation.42 What happens next depends on text nobody has seen, so plan for a proposal and comment period and keep your current review running under today's rule.

Two counts of TV drug ad spending since the letters, pointing in opposite directions

Neither count shows what the letters did. The first is measured by an industry group for TV advertising, so read it with that in mind. We read only an excerpt of the second, not the full article.

Longer ads give more room for risk, and more room for things to happen during it: one cancer ad's major statement runs from 0:32 to 1:13, and FDA still objected to the frequent scene changes.45

How much drug advertising there is to review: billions of dollars and over 70,000 submissions a year

In shortNational TV took nearly $6 billion of pharma ad money in 2025, by one count. FDA received over 70,000 Form 2253 submissions in 2024, holding over 150,000 pieces of promotion. FDA estimates about 570 consumer TV ads a year fall under the major statement rule.

Consumer drug advertising grew from $1.3 billion and 79,000 ads in 1997 to $6 billion and 4.6 million ads in 2016, including 663,000 TV commercials, in 2016 dollars.50

MLR, for medical, legal, regulatory, is the industry's name for the review meeting, and marketing teams often call it their bottleneck. The public benchmarks come from software vendors, and none is specific to TV. One vendor reports an average job of 14.8 days in 2025, a review of 7.6 days, and 1.5 circulations, or passes through the reviewers. A second vendor's 2021 report has 21 days, and EY's 2024 figure is 24, as quoted by Klick.51,52

Why risk passages drift out of balance, and what follows an FDA letter

In shortNobody sets out to bury risk. Scripts are approved before pictures exist; editors cut for energy; a cutdown, a shorter version of the spot, squeezes the same words into fewer seconds; templates go pale on bright backgrounds. A letter asks for a written response in 15 working days and is public. The cost after that is not published.

Eight ways a cut goes wrong, and why each one happens

Beyond the letter, two more costs are stated in law or by FDA. A warning letter, FDA's more severe notice, can ask for corrective communications, messages that set the record straight.27 And a false or misleading DTC ad can carry the civil money penalties set out in section 3.18 The bigger costs are the media already bought and the campaign that has to be rebuilt, which no one publishes.

What software can count on a drug ad, what stays with a reviewer, and what regulators say about AI

In shortFDA says it is using AI to watch ads. Software on the company's side can count shots, words and pixels and find similar past letters. "Likely to interfere" and "overall impression" stay with people, because FDA decides them case by case. No AI rule is aimed at ad review; the texts people cite have other scopes.

Where machine reading goes wrong on a cut

• A dissolve or a long camera move. A dissolve, one shot fading into the next, may read as no shot change, and so may a pan inside one shot. FDA can object to movement inside a shot.24
• A word it cannot hear. A voice over loud music is the very case where speech recognition is weakest. The tool should mark the word unclear, because an invented word would be worse than a gap.
• Text on a moving background. Contrast varies across a shot, so ask whether a tool measures the worst frame or an average.
• Reading a story. Telling that a picture "implies" more than the label supports is a judgment. Software can point to the shot and the label passage, and a medical reviewer has to say whether it holds.
• Similar letters. A letter found by similarity is a lead. Someone has to read it, and it is worth checking that the quoted passage is in the real letter.

Words to be careful with: no software product is "certified" or "compliant" with Part 11 or GxP, the family of good-practice quality rules. A vendor can offer controls that support your compliance, and your own validation of your use stays yours. FDA's Computer Software Assurance guidance covers device production and quality system software, so it does not apply here.

How promotional review committees check a TV cut today: who watches, who signs and where the days go

In shortSix roles carry a cut from script to filing. Regulatory leads, medical checks the label and legal signs. Comments go back and forth through a review system that routes files and leaves the watching to people. On a sample estimate, one round of a national TV cut takes a reviewer close to three days of their own time.

Regulatory, medical, legal, brand, agency and compliance operations: who holds which part of a cut

No regulation names these roles. Companies call the meeting MLR, PRC (promotional review committee) or RC, and titles and splits vary. FDA reviews what is submitted; the company's committee is its own control.

By hand, through an agency or with software: three ways to run the review

"Back to the everyday", cut 4: from 7:52 am arrival to a timecoded request to the agency

In shortThis is the example from the top of the page, inside the product. Six specialist agents, software workers with one job each, break the cut into shots, time it and match it to past letters. Priya Ranvelle, the regulatory advertising lead, sees the spot laid out as tracks, watches a scan stop at 0:42, decides five findings and sends one request. Every decision is hers.

1

The spot, laid out as tracks

AD-611 opens as an ad timeline: a strip of frames across 21 shots, with tracks for shot changes, voice-over in words per second, supers with their seconds on screen, and music in decibels. Benefit runs 0:00 to 0:31, the risk statement 0:31 to 0:52, and where to learn more 0:52 to 1:00. The spot bin above holds every TV, streaming and social cut in review.

Arrived at 7:52 am, airs October 26, in 19 days, on a $4.2 million flight.

2

The scan stops at 0:42

The playhead sweeps the spot and flags drop at their timestamps. At 0:42 the second risk super, "Serious allergic reactions · Liver problems · Get help right away", lands over barbecue, paddle splash, bike jump, diving for the ball and an outdoor concert. That is 8 shot changes in 9.5 seconds, or 8.4 per 10 seconds, against the company's limit of 3 and 1.9 in the benefit part.

The frame on the left shows the super as a viewer saw it, at its true relative size. It is hard to find.

3

Seven timings against seven limits

The fair-balance timing panel fills as the scan runs: 31 seconds against 21; 8.4 shot changes per 10 seconds at worst; 88% risk text coverage; 2.0% text height at 2.1 : 1; 3.2 words a second against 2.2; music 5 decibels up. Each row links to the sample letters on that theme.

The first row is informational on purpose. Time alone decides nothing, as section 2 explained.

4

Five findings, each for her to decide

Opening the review shows the cut, live meters and five findings, two high. Competing visuals: 14 shots in 21 seconds under the risks. Risk text missing for 12% of the major statement. Small, pale text. Risks read faster over louder music. A lifestyle montage that implies more than clearer skin.

Each finding carries its timestamp, its rule, the sample letters and a suggested revision. Priya has three choices each time: ask for revision, accept with a note, or not an issue. She asks for all five.

5

One request, with the numbers the next cut must meet

The Revision writer drafts a single request to Lena Ortiz at Harborline Health, copying Sam Patel and Omar Haddad. No more than 6 calm shots from 0:31 to 0:52. The risk super for the whole major statement, with every key term verbatim. 44 pixels or more on a dark band. 2.8 words a second or slower. Music down at least 6 decibels.

A person sends it, and it asks for the next cut by October 9.

Cut 5: re-measured as it lands, then signed twice

6

Four agents re-measure the next cut

Harborline uploads cut 5. The Media framer reads 10 shots, 4 supers and 142 timed words. The Claim & risk aligner finds 4 of 4 most-serious risks spoken. The Fair-balance timer measures 1.6 shot changes per 10 seconds, risk text for 100% of the major statement, and 2.5 against 2.2 words a second. The Precedent matcher finds no letter that matches.

7

Five issues fixed, eight checks passed

The review now reads "Every finding from cut v4 is resolved." The checks list what passed and by how much: 4.4% of frame height at 9.8 : 1, pace 1.13×, music 8 decibels down, four sources of adequate provision.

A careful reviewer still looks. Under (B), audio must be at least as understandable as the rest of the ad, so a voice 13% faster than the benefit part passes the company's setting and remains a question for a person's ear.2

8

Her signature, then legal's

Priya signs with the meaning "Approved for air — regulatory review". Her name, the meaning and the time are recorded. Because AD-611 is national TV, Omar Haddad, promotional legal counsel, is asked for the second signature next. Dr. Maya Chen had already confirmed the script's claims against the label.

9

The Form FDA 2253 package, ready for first use

Once both signatures are in, AD-611 is cleared to air. The Form 2253 packager builds the submission from the cleared cut: applicant, product, application, material ID AD-611-v5, first dissemination October 26, 2026, with the final cut, the script with timings, the current Prescribing Information and the sign-off record.

The packager prepares it, and Dana Okafor in compliance operations files it. The rule asks for submission at first publication with the current labeling.3,14

The other screens: meters on the major statement, the sample letter library, the air schedule and web pages

In shortThese screens show the review at the moment the risks start, the balance side by side, the words spoken, the sample letters, every creative (an ad, page or post in review) in one list, the schedule against air dates, the numbers leaders watch, the thresholds and who may change them, and the same review on a web page and a creator post.

Six agents frame, time and match each cut; the regulatory lead decides and legal signs on national TV

In shortEach agent has one job and limits it does not cross. None of them decides a finding, changes a threshold, sends a request or files a form. National TV takes a legal second signature, accepting a finding with a note takes a second person, and agencies see only their own work.

Regulatory decides, medical confirms, legal seconds and operations files

Each upload, agent step, decision, request, signature and package goes on the audit trail with who and when, agent steps and human decisions shown apart. The solution offers controls that support your compliance work under 21 CFR Part 11; your validation of its use stays yours. Botminds is SOC 2 Type II audited and manages information security to ISO 27001.

Priya, Omar, Maya, Sam and Lena: five of the six people on the Veltrimab spot

Cuts, scripts and labels in; a timed review, a timecoded request and a signed clearance out

In shortThe solution reads what your review already handles, and it leaves your review system, agencies and filing process in place. What it adds is a measurement of each cut, a finding with a timestamp and a rule, and one signed record. Outcome numbers below are design targets from the solution, to be measured in your own use.

Agency portals, review systems and the label library the review plugs into

What a round of revisions and a letter from FDA cost you in reviewer days and media money

In shortStart from your own costs, because no public figure exists for most of them. A few public facts frame the risk: how many TV ad letters FDA wrote, what share object to the major statement, and what your legal exposure is on paper. The rest you can measure in a week.

Timing ten cuts and pricing one slipped flight: finding your baseline in a week

Costs a review calculator will not count

What measuring each cut returns when you count reviewer hours, avoided rounds and media at risk

In shortPut in your own numbers. The calculator asks how many cuts you review, the rounds and hours each takes, what an hour costs, how many flights slip, and what the tool costs. No input has a public benchmark, so every default is marked illustrative or the solution's estimate. A letter avoided is left as a small input, since it is hard to price and easy to overstate.

Reviewer hours, fewer rounds and steadier air dates: where fair balance review saves

Cuts a year, hours a round and your cost of a slipped flight

If your company runs two brands with a few TV spots a year, the arithmetic on time alone will not reach break-even, and a good reviewer with a stopwatch and written limits may serve you better. Tell any vendor that before a demonstration. Cuts in every medium count toward volume, so a heavy social program can change this.

How ready your review team is: cut volume, written limits, label versions, letters and sign-off

In shortPick the answer closest to your team today. Eight questions score 0 to 2; the last is for reflection. The meter adds up your score as you go, and each question says why it matters and what a strong answer sounds like.

From 0 to 16: write your limits, pilot on past cuts, or plan the brands

What to ask any vendor of drug ad review software about shots, supers, letters and signatures

In shortAsk these of anyone, us included. The strong answers are specific and the warning signs are confident. Good vendors will show you a miss.

A six-week pilot on past cuts, with one brand, one agency and three numbers to decide on

In shortUse cuts that have already aired or been reworked, so nothing is at stake. Time your current process first. Measure the tool against what your reviewers found, and what they missed. Decide on three numbers: findings matched, false alarms and hours per round.

1. Pick the brand and collect ten cutsInclude the versions that drew heavy comment, one cutdown and one that aired cleanly.
2. Write your limitsStart with what your reviewers already use, then write down the reason for each one.
3. Time your current reviewReviewer minutes per step on three new cuts, for a true baseline.
4. Measure the past cuts and compareAgainst what your team and FDA's letters would object to. Count matches, misses and false alarms.
5. Run one live cut with the agency, and decideYour reviewer still signs. Then bring the numbers to the owner.

Keep people signing for the whole pilot. Nothing a pilot produces clears an ad on its own.

Findings matched, false alarms and hours per round: what a pilot should report

Ten cuts is a small sample. It can show whether the tool is worth further testing, and a clean pilot leaves room for what it will still miss. Keep a reviewer's eye on the things software cannot read, such as story and implied promise.

What people ask about fair balance in drug advertising

In shortEach answer stands alone. Rule status is as of November 2026.